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Introduction: Bone morphogenetic proteins (BMPs) are multifunctional secreted growth factors regulating a broad
spectrum of functions in numerous systems. An increased expression and production of specific BMPs have been
described in the rheumatoid arthritis (RA) synovium. The aim of this study was to analyze the involvement of the BMP
signaling pathway in RA synoviocytes in response to interleukin-17 (IL-17) and tumor necrosis factor-alpha (TNF-α).
Methods: The expression of components of the BMP signaling pathway (BMP receptors, BMP ligands, BMP signal
transducers, and BMP antagonists) was analyzed by quantitative polymerase chain reaction before and after
treatment of RA synoviocytes with TNF-α or IL-17 or both. Regulation was studied in the presence of the specific
BMP inhibitor DMH1 (dorsomorphin homologue 1) or an exogenous BMP ligand, BMP6. Expression and production of
pro-inflammatory cytokines (IL-6 and granulocyte-macrophage colony-stimulating factor), chemokines (IL-8, CCL2, CCL5,
and CXCL10), and matrix metalloproteinases (MMP-1, −2, −3, −9, and −13) were analyzed.
Results: RA synoviocytes express BMP receptors (mainly BMPRIA, ACTRIA, and BMPRII), signal transducers of the Smad
family (Smad1 and 5 and co-Smad4), and different BMP antagonists. The modulation of the expression of the BMP target
genes—Id (inhibitor of DNA-binding/differentiation) proteins and Runx (Runt-related transcription factor) transcription
factors—after the addition of exogenous BMP shows that the BMP signaling pathway is active. RA synoviocytes also
express BMP ligands (BMP2, BMP6, and BMP7) which are highly upregulated after activation with TNF-α and IL-17.
Autocrine BMP signaling pathway can be blocked by treatment with the inhibitor DMH1, leading to an increase in the
upregulated expression of pro-inflammatory cytokines, chemokines, and MMPs induced by the activation of RA
synoviocytes with TNF-α and IL-17. Conversely, the additional stimulation of the BMP pathway with the exogenous
addition of the BMP6 ligand decreases the expression of those pro-inflammatory and pro-destructive factors.
Conclusion: The results indicate that the canonical BMP pathway is functionally active in human RA synoviocytes and
that the inhibition of autocrine BMP signaling exacerbates the pro-inflammatory phenotype induced in RA synoviocytes
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Bone morphogenetic proteins (BMPs) are secreted signal-
ing proteins which form a subgroup of the transforming
growth factor-beta (TGF-β) superfamily [1]. BMPs are di-
meric proteins which, once secreted, bind to type I and
type II BMP receptors constituting multimeric receptor-
ligand complexes. Type II receptors are constitutively
active serine/threonine kinases which trans-phosphorylate
type I receptors upon ligand binding; subsequently, acti-
vated type I receptors phosphorylate and activate some
components of the Smad protein family, Smad1, 5, and 8,
called BMP receptor-regulated Smads (BR-Smads) [1–3].
The common mediator Smad4 next binds to BR-Smads,
and the heteromeric complexes translocate to the nucleus
to regulate the transcription of BMP target genes, includ-
ing Id (inhibitor of DNA-binding/differentiation) proteins
and Runx (Runt-related transcription factor) transcription
factors [1, 2]. In addition to this canonical signaling path-
way, activated BMP receptors may initiate non-canonical
Smad-independent signaling pathways [1].
BMPs were originally identified as growth and differenti-
ation factors for osteogenic cells but now are considered
multifunctional proteins implicated in the development of
virtually all organs and the renewal and maintenance of dif-
ferent adult tissues [1, 4–6]. The relevance of this pathway
is further emphasized by the fact that an aberrant BMP sig-
naling can result in several developmental defects and dis-
tinct human disorders, including cancer, chronic kidney
diseases, endocrine alterations, vascular diseases, and joint
and musculoskeletal disorders [7–10]. Rheumatoid arthritis
(RA) is the most common form of chronic inflammatory
arthritis characterized by persistent synovial inflammation,
articular damage, and altered immune response [11]. Sev-
eral BMP ligands, including BMP2, BMP6, and BMP7, have
been shown to be upregulated in the synovium of patients
with RA as well as in tumor necrosis factor-alpha (TNF-α)
transgenic mice developing arthritis and in collagen-
induced arthritis models [12–14]. High levels of BMP7
have also been demonstrated in the synovial fluid of pa-
tients with RA, and levels are correlated with severity
of disease [15]. In contrast, BMP4 and BMP5 ligands
are downregulated in the RA synovium [16]. In collagen-
induced arthritis, a dynamic activation of the BMP signal-
ing pathway has been reported, showing a time-dependent
increase of the amount of phosphorylated BR-Smads and
the number of phospho-Smad1/5/8-positive cells [13].
Furthermore, fibroblast-like synoviocytes from patients
with RA have been demonstrated to express BMP recep-
tors [17] and to upregulate the expression of BMP2 and
mainly BMP6 after stimulation with pro-inflammatory cy-
tokines such as TNF-α, interleukin-1beta (IL-1β), and
IL-17 [14, 18, 19].
Despite all these data, however, only a few studies have
addressed the involvement of BMP signaling in RA,pointing out a role for BMP6 and BMP7 in stimulating
the survival and the proliferation and extracellular matrix
component biosynthesis, respectively, in synoviocytes
[12, 14]. In the present study, we show that the canonical
BMP pathway is functionally active in human RA synovio-
cytes and that autocrine BMP signaling modulates the
expression of pro-inflammatory cytokines, chemokines,
and matrix metalloproteinases (MMPs).
Methods
Isolation and culture of rheumatoid arthritis synoviocytes
Synoviocytes were grown from synovial tissue samples ob-
tained from RA patients undergoing joint surgery. The
patients with RA fulfilled the American College of
Rheumatology criteria for RA [20]. Each individual signed
an informed consent form, and the protocol was approved
by the committee for the protection of persons participat-
ing in biomedical research of the Hospital of Lyon, in
compliance with the Helsinki Declaration. Briefly, synovial
tissue was minced in small pieces which were allowed
to fix on plastic plates. Those samples were maintained in
Dulbecco’s modified Eagle’s medium (Eurobio, Courtaboeuf,
France) supplemented with 10 % fetal bovine serum
(Life Technologies, part of Thermo Fisher Scientific,
Carlsbad, CA, USA), 2 % Penicillin-Streptomycin (Eurobio),
1 % L-glutamine (Eurobio), and 1 % Amphotericin B
(Eurobio) until cells grew out of the tissue and colonized
the plastic dishes. After cells reached confluence, tissue
pieces were removed and cells were trypsinized. Synovio-
cytes were used between passages 4 and 9. Each independ-
ent experiment was performed with a different batch of
synoviocytes isolated from different RA donors.
RNA extraction and purification
Cells were seeded in 12-well plates at a density of 5×104
cells/cm2. Cells then were treated for 12 h with different
combinations of IL-17 50 ng/mL (R&D Systems, Minne-
apolis, MN, USA), TNF-α 0.5 ng/mL (R&D Systems),
BMP-6 10 ng/mL (HumanZyme, Chicago, IL, USA), and
dorsomorphin homologue 1 (DMH1) 30 μM (Tocris
Bioscience, Ellisville, MO, USA). After 12-h treatment,
RNA was extracted by using an RNeasy Plus Mini Kit
(Qiagen, Venlo, Limburg, The Netherlands) in accordance
with the instructions of the manufacturer. RNA then
was quantified by using a Qubit RNA BR Assay Kit
(Life Technologies).
Real-time quantitative reverse transcription-polymerase
chain reaction
Total cDNA was synthesized by using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Waltham, MA, USA) in accordance with the instructions
of the supplier and then used as a target in the polymerase
chain reaction (PCR) amplifications. Pre-designed TaqMan
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tained from Applied Biosystems. GNB2L1 was used as
an endogenous control. All PCRs were set in duplicates
by using the TaqMan Gene Expression Master Mix
(Applied Biosystems) in accordance with the instructions
of the manufacturer. Amplifications, detections, and
analyses were performed in a 7.900HT Fast Real-time
PCR System (Centro de Genómica, Complutense Uni-
versity, Madrid, Spain). The ΔCt method was used for
normalization to GNB2L1.Cytokine measurements
Culture supernatants of RA synoviocytes were harvested
after 12 h of treatment. IL-8 secretion was measured by
using an enzyme-linked immunosorbent assay (BioLegend,
San Diego, CA, USA) and IL-6 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were
measured by using Cytometric Bead Array assays (BD
Biosciences, Franklin Lakes, NJ, USA) in accordance
with the instructions of the manufacturers.Statistical analysis
The Mann–Whitney test was used to compare differences.
Values of P ≤ 0.05 (*), P ≤ 0.01 (**), and P ≤ 0.001 (***)
were considered to be statistically significant.Fig. 1 Expression of canonical BMP signaling components in RA synoviocy
patients with RA were used between passages 4 and 9 to study the expres
by quantitative reverse transcription-polymerase chain reaction. Frames show
family components, d BMP target genes, and e BMP antagonists. GNB2L1 wa
deviation) of three to five independent experiments. ACTRIA type IA activin re
BAMBI bone morphogenetic protein and activin membrane-bound inhibitor,
protein receptor, BMPRIB type IB bone morphogenetic protein receptor, B
DNA-binding/differentiation, RA rheumatoid arthritis, Runx Runt-related transcResults
Bone morphogenetic protein signaling pathway is
functionally active in human rheumatoid arthritis
synoviocytes
The expression of different components of the BMP sig-
naling pathway was analyzed in RA synoviocytes. BMP
receptor complexes are constituted by one of the follow-
ing type I receptors, type IA BMP receptor (BMPRIA)/
ALK-3, type IB BMP receptor (BMPRIB)/ALK-6, and
type IA activin receptor (ACTRIA)/ALK-2, which com-
monly combine with type II BMP receptor (BMPRII) but
also the type IIA and IIB activin receptors (ACTRIIA and
ACTRIIB). In RA synoviocytes, BMPRIA and ACTRIA
were the most abundantly expressed type I receptors, and
the BMP-specific type II receptor BMPRII showed a high
level of expression (Fig. 1a).
Among ligands, the most highly expressed were BMP2
and BMP6 (Fig. 1b). Synoviocytes also expressed specific
RNAs for the Smad signal transducers, Smad1, Smad5,
and the common partner Smad4, as well as the well-known
BMP target genes, the Id protein family and Runx tran-
scription factors [1] (Fig. 1c, d).
Furthermore, BMP signaling is finely regulated at
multiple levels: at the extracellular space, several high-
affinity antagonists bind selectively with BMPs to inhibit
their biological actions; at the plasma membrane, thetes. Synoviocytes grown from synovial tissue samples obtained from
sion of several components of the canonical BMP signaling pathway
the mRNA levels for a BMP receptors, b BMP ligands, c Smad protein
s used as an endogenous control. Bars represent the mean (± standard
ceptor, ACTRIIA type IIA activin receptor, ACTRIIB type IIB activin receptor,
BMP bone morphogenetic protein, BMPRIA type IA bone morphogenetic
MPRII type II bone morphogenetic protein receptor, Id inhibitor of
ription factor, Smad small mother against decapentaplegic homolog
Fig. 2 Modulation of BMP target gene expression in response to
exogenous BMP stimulation. Synoviocytes from patients with
rheumatoid arthritis were cultured in media alone (CTRL) or in the
presence of increasing concentrations of BMP6 (1–100 ng/mL). After
12 h, cells were harvested and the expression of several target
genes—Id1-4 a and Runx1-3 b factors—was analyzed by quantitative
reverse transcription-polymerase chain reaction. GNB2L1 was used as
an endogenous control. Results represent increments relative to
cultures with media alone. The mean (± standard deviation) of
three independent experiments is shown. BMP bone morphogenetic
protein, CTRL control, Id inhibitor of DNA-binding/differentiation, Runx
Runt-related transcription factor
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preventing the formation of active receptor complexes;
and intracellularly, inhibitory Smads and Smurfs inhibit
further signaling and activation of target genes [21].
The expression of different BMP antagonists was also
detected in RA synoviocytes, mainly the extracellular
antagonist Twisted gastrulation and the intracellular in-
hibitors Smad6 and Smad7 (Fig. 1e). In contrast, only
low levels of the pseudoreceptor BAMBI and the extra-
cellular antagonists Noggin and Chordin could be de-
tected in non-stimulated RA synoviocytes (Fig. 1e).
The functionality of the BMP pathway was analyzed by
studying the modulation of the expression of the compo-
nents of Id protein and Runx families after addition of
exogenous BMP. As shown in Fig. 2, stimulation of BMP
signaling in synoviocytes showed a dose-dependent trend
to increase the mRNA levels of Id1, Id2, and mainly Id3
and Runx2. On the contrary, the levels of transcripts for
Id4 and Runx3 tended to decrease after BMP stimulation
(Fig. 2a, b). These data indicated that BMP signaling
pathway is functional in RA synoviocytes.
Expression of bone morphogenetic protein pathway
components is upregulated by pro-inflammatory cytokines
in rheumatoid arthritis synoviocytes
We next examined the effects of critical pro-inflammatory
cytokines in RA, such as TNF-α and IL-17, on the ex-
pression of the different components of the BMP sig-
naling pathway. The culture of synoviocytes with IL-17
and TNF-α alone or in combination induced mainly a
3- to 4-fold increase in the expression of BMPRIB, the
least expressed type I BMP receptor in unstimulated
synoviocytes, and slight increases in the mRNA levels
of BMPRII and ACTRIIB receptors (Fig. 3a). The ex-
pression of Smad transcripts was hardly affected by the
pro-inflammatory treatment. In contrast, the expression
of BMP2, BMP6, and BMP7 ligands was notably increased
after culture with IL-17 and TNF-α and mainly when
the two cytokines were used in combination (8-, 9-, and
20-fold increases for BMP2, BMP6, and BMP7, respect-
ively) (Fig. 3b, c). The levels of BMP4 mRNA were,
however, reduced mainly in the presence of TNF-α
(Fig. 3b). Interestingly, stimulation with TNF-α alone or
with IL-17 enhanced the levels of transcripts encoding
the membrane-bound antagonist BAMBI and the intra-
cellular inhibitor Smad7 (3- to 5-fold and 2- to 3-fold
increases, respectively) and, to a lesser extent, the extracel-
lular modulator Twisted gastrulation (Fig. 3d).
Blockade of canonical bone morphogenetic protein
signaling potentiates cytokine production in rheumatoid
arthritis synoviocytes
The above data showing BMP receptor expression on
synoviocytes, along with an upregulated BMP expressionafter pro-inflammatory cytokine stimulation, suggested
that BMP ligands produced by RA synoviocytes could
act in an autocrine manner. The highly selective type I
BMP receptor inhibitor DMH1, which blocks the canonical
BMP signaling pathway by inhibiting the BMP-induced
Smad 1/5/8 activation [22], was used to study the role of
endogenously produced BMP ligands in the expression of
inflammatory factors in synoviocytes. As reported [18],
IL-17, TNF-α, and mainly the combination of the two
cytokines mostly upregulated the expression levels of
the pro-inflammatory cytokines IL-6 and GM-CSF as well
as the chemokine IL-8, all involved in RA pathogenesis
(Fig. 4a). Remarkably, the simultaneous blockade of the
canonical BMP signaling pathway induced a further
Fig. 3 Regulation of BMP pathway components by pro-inflammatory cytokines. Rheumatoid arthritis synoviocytes were cultured in media alone
(CTRL) or in the presence of IL-17 (50 ng/mL) or TNF-α (0.5 ng/mL) or both. a-d Expression of several BMP pathway components, including a
BMP receptors, b BMP ligands, c Smad protein family components and d BMP antagonists, was studied by quantitative reverse transcription-
polymerase chain reaction after 12 h of culture. GNB2L1 was used as an endogenous control. Results represent increments in respect to cultures
in media alone. The mean (± standard deviation) of three independent experiments is shown. ACTRIA type IA activin receptor, ACTRIIA type IIA
activin receptor, ACTRIIB type IIB activin receptor, BAMBI bone morphogenetic protein and activin membrane-bound inhibitor, BMP bone morphogenetic
protein, BMPRIA type IA bone morphogenetic protein receptor, BMPRIB type IB bone morphogenetic protein receptor, BMPRII type II bone morphogenetic
protein receptor, CTRL control, IL-17 interleukin-17, Smad small mother against decapentaplegic homolog, TNF-α tumor necrosis factor-alpha
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some cases the higher levels reached after treatment with
IL-17 or TNF-α or both underwent a further 2- to 3-fold
increase (Fig. 4a). When protein levels were measured
in the culture supernatants, the secretion of IL-8 and
GM-CSF was also notably increased after treatment
with the BMP inhibitor DMH1 (Fig. 4b). No significant
variations were seen when IL-6 protein levels were de-
termined (Fig. 4b). Therefore, these results suggested an
anti-inflammatory role for BMP signaling.Modulation of chemokine and metalloproteinase
expression in rheumatoid arthritis synoviocytes after
canonical bone morphogenetic protein signaling
inhibition
The expression of chemokines other than IL-8 was ana-
lyzed, and the results showed that BMP signaling inhib-
ition mainly augmented the expression of CCL2 induced
by IL-17 (Fig. 5a). However, the presence of the BMP in-
hibitor DMH1 did not significantly alter the expression
of CCL2 and CCL5 or markedly reduced the high
Fig. 4 Effects of BMP signaling blockade on TNF-α- and IL-17-induced cytokine and chemokine mRNA and protein expression in RA synoviocytes.
RA synoviocytes were simultaneously treated with the BMP pathway inhibitor DMH1 and IL-17 (50 ng/mL) or TNF-α (0.5 ng/mL) or both. a After
12 h, mRNA levels were analyzed by quantitative reverse transcription-polymerase chain reaction. Cells were left untreated as control, and the fold
induction is shown for each treatment. GNB2L1 was used as an endogenous control. Bars represent the mean (± SD) of four to six independent
experiments. Asterisks represent statistically significant differences between DMH1-treated and DMH1-non-treated cells (*P ≤0.05; **P ≤0.01; ***P ≤0.005;
by Mann–Whitney test). b Protein levels were determined by enzyme-linked immunosorbent assay/Cytometric Bead Array assays. Data shown
are expressed as fold induction compared with the untreated condition. Asterisks represent statistically significant differences between DMH1-treated
and DMH1-non-treated cells (*P ≤0.05; **P ≤0.01; ***P ≤0.005; by t test). Bars represent the mean (± SD) of three to five independent experiments.
BMP bone morphogenetic protein, CTRL control, DMH1 dorsomorphin homologue 1, GM-CSF granulocyte-macrophage colony-stimulating factor, IL
interleukin, MMP matrix metalloproteinase, RA rheumatoid arthritis, SD standard deviation, TNF-α tumor necrosis factor-alpha
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TNF-α alone or in combination with IL-17 (Fig. 5a).
The treatment of RA synoviocytes with IL-17 or TNF-α
or both also upregulated the expression of MMP-2 and
MMP-3 metalloproteinases involved in synoviocyte migra-
tion and invasion as well as joint destruction [18, 23]
(Fig. 5b). When the canonical BMP signaling pathway was
simultaneously inhibited by the addition of DMH1, the
expression of both metalloproteinases underwent a fur-
ther significant increase, mainly after treatment with
TNF-α alone or together with IL-17 (Fig. 5b). In con-
trast, the upregulation of MMP-1, MMP-9, and MMP-
13 metalloproteinase expression induced by IL-17 and
TNF-α [24] was not significantly affected by the block-
ade of BMP signaling (Fig. 5b).
Effects of the addition of BMP6 on cytokine, chemokine,
and metalloproteinase expression in rheumatoid arthritis
synoviocytes
The effects of the addition of an exogenous BMP ligand,
inducing an additional BMP signaling pathway activation,
were also addressed. BMP6 was chosen because of its
notable expression levels in RA synoviocytes and its
high upregulation after synoviocyte stimulation with pro-inflammatory cytokines (Figs. 1b and 3b). Remarkably, in
non-stimulated RA synoviocytes, cultured in the absence
of IL-17 or TNF-α, the expression of IL-6, GM-CSF, and
IL-8 was reduced by 50–70 % by the presence of BMP6,
and to a lesser extent CCL2, MMP-3, and MMP-13
expression was reduced by 40 % (Fig. 6a). No relevant
changes were observed in the expression of the metal-
loproteinases MMP-2, MMP-1, and MMP-9 and the
chemokines CCL5 and CXCL10 (Fig. 6a). Meanwhile,
in cytokine-activated RA synoviocytes, it could be noted
that the further stimulation of BMP signaling tended to
decrease the expression of most of the studied genes,
mainly when TNF-α was present (Fig. 6b). No consistent
differences were observed for the expression of MMP-1,
MMP-9, and MMP-13 metalloproteinases after BMP
ligand addition (not shown). All these data, then, sup-
ported the idea that the BMP pathway would have anti-
inflammatory effects.
Discussion
The increased expression and production of specific BMPs
(i.e., BMP2, BMP6, and BMP7) in the synovium and
synovial fluid of patients with RA as well as in mouse
models of arthritis have been reported by different groups
Fig. 5 Effects of bone morphogenetic protein inhibitor DMH1 treatment on TNF-α and IL-17 combination-induced chemokine and matrix
metalloproteinase mRNA expression in RA synoviocytes. Synoviocytes from patients with RA were left untreated (CTRL) or stimulated with
IL-17 (50 ng/mL) or TNF-α (0.5 ng/mL) or both in the presence or absence of DMH1. The expression of a the indicated chemokines and b matrix
metalloproteinases was analyzed by quantitative reverse transcription-polymerase chain reaction after 12 h of culture. GNB2L1 was used as an
endogenous control. Fold induction relative to untreated cells is shown, and the mean (± standard deviation) of four to six independent experiments is
presented. Asterisks represent statistically significant differences between DMH1-non-treated and DMH1-treated cells (*P ≤0.05; **P ≤0.01; ***P ≤0.005; by
Mann–Whitney test). CCL2 chemokine (C-C motif) ligand 2, CCL5 chemokine (C-C motif) ligand 5, CTRL control, CXCL10 chemokine (C-X-C motif) ligand 10,
DMH1 dorsomorphin homologue 1, IL-17 interleukin-17, MMP matrix metalloproteinase, RA rheumatoid arthritis, TNF-α tumor necrosis factor-alpha
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pathway in RA pathogenesis has been poorly analyzed.
In this study, we show the presence of a functionally
active BMP signaling pathway in synoviocytes. Human
RA synoviocytes express the three type I BMP receptors,
BMPRIA, BMPRIB, and ACTRIA, and the BMP-specific
type II receptor BMPRII. RA synoviocytes also express
the BR-Smads as well as the common partner Smad4.
All of these components are found to be efficient in sig-
nal transduction given the ability of synoviocytes to
modulate the expression of some BMP target genes, in-
cluding some Runx factors and members of the Id pro-
tein family, in response to exogenous BMP stimulation.
In addition, RA synoviocytes express BMP ligands which,
in agreement with previous work [14, 18, 19], are notably
upregulated after stimulation with pro-inflammatory cyto-
kines. These data suggest that some functional activities of
synoviocytes could be modulated by BMP in an autocrinefashion, which is supported by our results using the select-
ive BMP inhibitor DMH1.
The blockade of BMP signaling with DMH1 significantly
enhances the expression of pro-inflammatory cytokines
(i.e., IL-6 and GM-CSF), chemokines (i.e., IL-8, CCL2, and
CCL5), and MMPs (i.e., MMP-2 and MMP-3) induced
in RA synoviocytes by the simultaneous treatment with
IL-17 and TNF-α alone or in combination. Conversely,
the stimulation of the BMP signaling pathway with an
exogenous BMP ligand reduces the expression of pro-
inflammatory and pro-destructive factors in both un-
stimulated and stimulated RA synoviocytes, mainly with
the IL-17 and TNF-α combination. Therefore, it could
be hypothesized that BMP signaling could have an anti-
inflammatory role in the control and maintenance of
low levels of pro-inflammatory factors in healthy syno-
viocytes and probably also in the early stages of RA
(Fig. 7). In this regard, Lories and Luyten [25] also
Fig. 6 Effects of exogenous BMP6 stimulation on cytokine, chemokine, and matrix metalloproteinase expression in RA synoviocytes. a The expression
of the indicated pro-inflammatory factors was analyzed by qRT-PCR in RA synoviocytes cultured in media alone (CTRL) or supplemented with BMP6
(10 ng/mL) for 12 h. b RA synoviocyte cultures were treated with IL-17 (50 ng/mL) or TNF-α (0.5 ng/mL) or both in the presence or absence of BMP6.
After 12 h, mRNA levels for the indicated factors were analyzed by qRT-PCR. Cells were left untreated as control, and the fold induction is shown for
each treatment. GNB2L1 was used as an endogenous control. Bars represent the mean (± standard deviation) of four to six independent experiments.
Asterisks represent statistically significant differences between BMP6-treated and -non-treated cells (*P ≤0.05; **P ≤0.01; ***P ≤0.005; by Mann–Whitney
test). BMP bone morphogenetic protein, CCL2 chemokine (C-C motif) ligand 2, CCL5 chemokine (C-C motif) ligand 5, CTRL control, CXCL10 chemokine
(C-X-C motif) ligand 10, GM-CSF granulocyte-macrophage colony-stimulating factor, IL interleukin, MMP matrix metalloproteinase, qRT-PCR quantitative
reverse transcription-polymerase chain reaction, RA rheumatoid arthritis, TNF-α tumor necrosis factor-alpha
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joint-protective factors since BMP2 was described to
promote synoviocyte apoptosis. Likewise, BMP7 has been
shown to be able to suppress alterations in synoviocytes
induced by synovial fluid from patients with RA, pointing
out a role for BMP in maintaining a quiescent phenotype
of the synovial lining layer [26].
However, the stimulation of RA synoviocytes induces
the expression not only of BMP ligands but also of BMP
antagonists, mainly after treatment with TNF-α alone
or in combination with IL-17. Smad7 and BAMBI are
the main upregulated BMP antagonists, which act at the
intracellular and the plasma membrane level, respectively
[21], indicating that BMP signaling inhibition must occur
in the synoviocytes themselves. This finding suggests that
in late stages of RA the BMP signaling pathway probablyis no longer able to control and maintain the low levels of
pro-inflammatory factors, which then will rise and persist
at chronically high levels contributing to RA pathogenesis
[27] (Fig. 7).
In this context, the high levels of BMP ligands pro-
duced by stimulated synoviocytes could also contribute
to the chronic inflammation associated with RA by act-
ing in a paracrine fashion on surrounding cells present
in the inflamed synovium (Fig. 7). BMPs have been shown
to induce a pro-inflammatory phenotype in endothelial
cells [28, 29] and to stimulate chemotactic responses in
monocytes/macrophages [30, 31], which play a central
role in RA. BMP pathway activation increases monocyte
adherence to endothelial cells [28] and stimulates the pro-
duction of pro-inflammatory cytokines, including TNF-α,
IL-1, and IL-6, by macrophages [32, 33]. We and others
Fig. 7 Schematic representation of BMP involvement in rheumatoid arthritis pathogenesis. Under steady-state conditions, autocrine BMP production could
downregulate the expression and contribute to keep low levels of pro-inflammatory cytokines and chemokines as well as matrix metalloproteinases in
synoviocytes. In the presence of increased levels of TNF-α and IL-17, synoviocytes become activated and enhance the production of BMPs which, however,
could no longer control the levels of pro-inflammatory and pro-destructive factors because of the simultaneous upregulated expression of BMP signaling
inhibitors in synoviocytes. Increased levels of BMPs could then participate in the recruitment and activation of immune cells contributing to rheumatoid
arthritis along with the increased levels of pro-inflammatory cytokines, chemokines, and metalloproteinases. BMP bone morphogenetic protein,
CCL2 chemokine (C-C motif) ligand 2, CCL5 chemokine (C-C motif) ligand 5, GM-CSF granulocyte-macrophage colony-stimulating factor, IL interleukin,
MMP matrix metalloproteinase, TNF-α tumor necrosis factor-alpha
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of dendritic cells [34], increases T-cell proliferation and
activation [35, 36], and promotes T helper 17 (Th17)
differentiation [36]. Furthermore, BMPs have been shown
to be chemotactic for mesenchymal stem cells [37–39],
which can expand Th17 cells, as we reported previously
[40], and osteoclast differentiation and activity can also be
enhanced by some BMP ligands [41], which could contrib-
ute to the bone destruction seen in RA.
Conclusions
We propose that BMPs would play a dual role in the
synovium, controlling the production of pro-inflammatory
cytokines and inhibiting synoviocyte transformation in
healthy and non-inflammatory conditions, but in advanced
stages of RA could contribute to chronic inflammation,
allowing the functional deregulation of synoviocytes and
promoting the activation and pro-inflammatory functions
of immune and non-immune cells accumulating in the in-
flamed arthritic joint.
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